Military Wiki
in: Pages using infobox Christian leader with unknown parameters, Articles incorporating text from Wikipedia, Living people,
and 7 more

Jay Houston Hoofnagle

Sign in to edit
Jay Houston Hoofnagle
Personal details
Born1943
NationalityUSA
Alma materYale, University of Virginia

Jay Houston Hoofnagle is an American M.D. He is a leading expert in hepatotoxicity, hepatitis, cirrhosis and other diseases of the liver, and director of the Liver Disease Research Branch in the Division of Digestive Diseases and Nutrition at the National Institutes of Health.[1]

Hoofnagle performed the first clinical trial on interferon for chronic hepatitis B. While it was believed that hepatitis was untreatable in the 1980s, Hoofnagle's trials at the National Institutes of Health using interferon during that period resulted in the first cures of hepatitis C infected patients.[2] His graduate work is notable for elucidating serologic response to hepatitis infection and is included in many textbook descriptions of hepatitis infection as a classic piece of virology. Hoofnagle is the author of over 500 peer reviewed articles on liver diseases, and his Scopus h-index as of August 2019 is 120.[3]

Career[]

Hoofnagle leads the Liver Disease Research Branch at NIDDK,[4] and has done so since he was tapped for the position in 2003.[5] In this capacity, Hoofnagle oversees the Drug-Induced Liver Injury Network and LiverTox, a database that provides "comprehensive and unbiased information about drug induced liver injury caused by prescription and nonprescription drugs, herbal and dietary supplements."[6] Data produced from this network showed that dietary supplements account for nearly 20 percent of drug-induced liver injuries.[7]

Prior to his current role, Hoofnagle was the Director of the Division of Digestive Diseases and Nutrition at the National Institute of Diabetes & Digestive & Kidney Diseases. Before joining the NIH, he was a senior scientist at the Hepatitis Branch, Division of Blood and Blood Products, Food and Drug Administration. Commissioned in the Public Health Service in 1978, he rose to the rank of Captain before retirement from the PHS and switch to Civil Service.

Education and training[]

  • Fellow in gastroenterology and hepatology, VA Hospital, Washington, D.C., 1976–78
  • Medical residency, VA Hospital, Washington, D.C., 1975–76
  • Staff fellow, Bureau of Biologics, Food and Drug Administration, Bethesda, Maryland, 1973–75
  • Resident in internal medicine, University of Virginia Hospital, 1972
  • Medical intern, University of Virginia Hospital, 1971
  • M.D., Yale University, 1970
  • BA, German Literature, University of Virginia, 1965

Awards[]

  • NIH Director's Award 2013, For outstanding contributions to the development and implementation of the DHHS Action Plan for the Prevention, Care & Treatment of Viral Hepatitis[8]
  • Hepatitis B Foundation Distinguished Scientist 2003, for outstanding contributions to advancing out the Foundation's "Cause for a Cure."[9]
  • American Association for the Study of Liver diseases distinguished achievement award 2001[10]
  • Gold Medal from the Canadian Association for the Study of the Liver 2001, for contributions to liver disease research.[11]

Books[]

References[]

  1. ↑ NIH, Jay H. Hoofnagle, M.D., http://www.niddk.nih.gov/about-niddk/staff-directory/extramural/jay-hoofnagle/pages/biography.aspx
  2. ↑ NIH, New NIDDK Branch Focuses on Liver Disease, Jul. 22, 2003, http://nihrecord.od.nih.gov/newsletters/07_22_2003/story05.htm Archived 2013-03-27 at the Wayback Machine.
  3. ↑ Author Details, Hoofnagle, Jay H. Aug. 2019 https://www.scopus.com/authid/detail.uri?authorId=7102238762
  4. ↑ Peter Jaret, Expert Q&A, The Difficult Road of Hepatitis C Treatment, New York Times, Aug. 14, 2008 https://www.nytimes.com/ref/health/healthguide/esn-hepatitisC-expert.html
  5. ↑ NIH, New NIDDK Branch Focuses on Liver Disease, Jul. 22, 2003, http://nihrecord.od.nih.gov/newsletters/07_22_2003/story05.htm Archived 2013-03-27 at the Wayback Machine.
  6. ↑ About Livertox, http://www.livertox.nih.gov/aboutus.html
  7. ↑ Anahad O'Connor, Spike in Harm to Liver Is Tied to Dietary Aids, New York TImes, Dec. 13, 2013 https://www.nytimes.com/2013/12/22/us/spike-in-harm-to-liver-is-tied-to-dietary-aids.html?hp&_r=0
  8. ↑ NIH, NIH Director's Awards Ceremony, 2013, http://hr.od.nih.gov/performance/awards/documents/2013NIHDirectorsAwardsCeremonyBrochure.pdf
  9. ↑ Dr. Jay Hoofnagle Honored by the HBF, Apr. 2003, http://www.hepb.org/about/hufnagle.htm Archived 2014-02-01 at the Wayback Machine.
  10. ↑ NIDDK's Hoofnagle Honored, Dec. 11, 2001, http://nihrecord.od.nih.gov/newsletters/12_11_2001/awardees.htm Archived 2013-03-27 at the Wayback Machine.
  11. ↑ Canada Liver Foundation, CLF-CASLGold Medal Award, http://www.liver.ca/who-we-are/clf-awards/gold-medal-award.aspx
  12. ↑ Guardia, Jaime. 2000. "Book Review Hepatitis C (Biomedical Research Reports.) Edited by T. Jake Liang and Jay H. Hoofnagle. 493 pp., illustrated. San Diego, Calif., Academic Press, 2000. $99.95. 0-12-447870-0". New England Journal of Medicine. 343 (25): 1899-1900, http://www.nejm.org/doi/full/10.1056/NEJM200012213432517

External links[]

All or a portion of this article consists of text from Wikipedia, and is therefore Creative Commons Licensed under GFDL.
The original article can be found at Jay Houston Hoofnagle and the edit history here.
Community content is available under CC-BY-SA unless otherwise noted.